NASDAQ:ORTXOrchard Therapeutics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Orchard Therapeutics PLC - Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $9.32 -0.28 (-2.92 %) (As of 05/25/2020 04:00 PM ET) Add Compare Share Today's Range$9.18Now: $9.32▼$9.8550-Day Range$7.51MA: $10.06▼$11.9952-Week Range$5.17Now: $9.32▼$19.23Volume162,000 shsAverage Volume346,466 shsMarket Capitalization$906.50 millionP/E RatioN/ADividend YieldN/ABeta1.24 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsInsider TradesInstitutional OwnershipHeadlinesSocial Media Orchard Therapeutics plc, integrated biopharmaceutical company, develops gene therapies for serious and life-threatening rare diseases. The company's gene therapy approach seeks to transform a patient's hematopoietic stem cells into a gene-modified drug product to treat the patient's disease through a single administration. Its commercial stage products include Strimvelis, a gammaretroviral-based product for the treatment of adenosine deaminase-severe combined immunodeficiency (ADA-SCID). The company's clinical development products comprise OTL-101 for the treatment of ADA-SCID; OTL-200 to treat metachromatic leukodystrophy; OTL-103 for the treatment of Wiskott-Aldrich syndrome; OTL-102 for X-linked chronic granulomatous disease; and OTL-300 for transfusion-dependent beta-thalassemia. Its preclinical programs include OTL-201 for mucopolysaccharidosis type IIIA and OTL-202 for mucopolysaccharidosis type IIIB. The company was formerly known as Orchard Rx Ltd. Orchard Therapeutics plc was founded in 2015 and is headquartered in London, the United Kingdom.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingOrchard Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $24.60, Orchard Therapeutics has a potential upside of 163.9% from its current price of $9.32.Amount of Analyst CoverageOrchard Therapeutics has only been the subject of 2 research reports in the past 90 days. Previous Next 2.2 Community Rank Outperform VotesOrchard Therapeutics has received 131 “outperform” votes. (Add your “outperform” vote.)Underperform VotesOrchard Therapeutics has received 161 “underperform” votes. (Add your “underperform” vote.)Community SentimentOrchard Therapeutics has received 55.14% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Orchard Therapeutics and other stocks. Vote “Outperform” if you believe ORTX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ORTX will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldOrchard Therapeutics does not currently pay a dividend.Dividend GrowthOrchard Therapeutics does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Orchard Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.20% of the stock of Orchard Therapeutics is held by insiders.Percentage Held by Institutions68.90% of the stock of Orchard Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Orchard Therapeutics are expected to grow in the coming year, from ($1.91) to ($1.79) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Orchard Therapeutics is -4.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Orchard Therapeutics is -4.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioOrchard Therapeutics has a P/B Ratio of 3.00. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 2.2Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.47 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ORTX Previous Symbol CUSIPN/A CIKN/A Webwww.orchard-tx.com Phone011-44-0-203-3846700Debt Debt-to-Equity Ratio0.09 Current Ratio6.66 Quick Ratio6.66Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$2.51 million Price / Sales361.16 Cash FlowN/A Price / Cash FlowN/A Book Value$3.11 per share Price / Book3.00Profitability EPS (Most Recent Fiscal Year)($1.75) Net Income$-163,420,000.00 Net MarginsN/A Return on Equity-57.51% Return on Assets-45.05%Miscellaneous Employees180 Outstanding Shares97,264,000Market Cap$906.50 million Next Earnings Date8/13/2020 (Estimated) OptionableNot Optionable NASDAQ:ORTX Rates by TradingView Receive ORTX News and Ratings via Email Sign-up to receive the latest news and ratings for ORTX and its competitors with MarketBeat's FREE daily newsletter. Orchard Therapeutics (NASDAQ:ORTX) Frequently Asked Questions How has Orchard Therapeutics' stock been impacted by COVID-19 (Coronavirus)? Orchard Therapeutics' stock was trading at $9.08 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, ORTX shares have increased by 2.6% and is now trading at $9.32. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Orchard Therapeutics? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Orchard Therapeutics in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Orchard Therapeutics. When is Orchard Therapeutics' next earnings date? Orchard Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Orchard Therapeutics. How were Orchard Therapeutics' earnings last quarter? Orchard Therapeutics PLC - (NASDAQ:ORTX) announced its quarterly earnings results on Thursday, May, 7th. The company reported ($0.51) EPS for the quarter, missing the Zacks' consensus estimate of ($0.50) by $0.01. View Orchard Therapeutics' earnings history. What price target have analysts set for ORTX? 5 brokers have issued 12 month price objectives for Orchard Therapeutics' shares. Their forecasts range from $17.00 to $31.00. On average, they expect Orchard Therapeutics' stock price to reach $24.60 in the next twelve months. This suggests a possible upside of 163.9% from the stock's current price. View analysts' price targets for Orchard Therapeutics. Has Orchard Therapeutics been receiving favorable news coverage? News headlines about ORTX stock have been trending negative recently, according to InfoTrie. The research group identifies positive and negative news coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Orchard Therapeutics earned a news impact score of -2.7 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View the latest news aboutOrchard Therapeutics. Who are some of Orchard Therapeutics' key competitors? Some companies that are related to Orchard Therapeutics include Halozyme Therapeutics (HALO), Fate Therapeutics (FATE), Denali Therapeutics (DNLI), Novavax (NVAX), Alector (ALEC), Bill.com (RVMD), SpringWorks Therapeutics (SWTX), Editas Medicine (EDIT), Adverum Biotechnologies (ADVM), Sangamo Therapeutics (SGMO), Cortexyme (CRTX), Regenxbio (RGNX), Twist Bioscience (TWST), I-Mab (BDTX) and Mesoblast (MESO). View all competitors. What other stocks do shareholders of Orchard Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Orchard Therapeutics investors own include Range Resources (RRC), bluebird bio (BLUE), Callon Petroleum (CPE), Iovance Biotherapeutics (IOVA), Applied Genetic Technologies (AGTC), Coeur Mining (CDE), Eiger Biopharmaceuticals (EIGR), Heron Therapeutics (HRTX), MEI Pharma (MEIP) and Myovant Sciences (MYOV). Who are Orchard Therapeutics' key executives? Orchard Therapeutics' management team includes the following people: Mr. Mark A. Rothera, CEO, Pres & Director (Age 56)Dr. Anne Dupraz-Poiseau, Chief Regulatory OfficerMr. Frank E. Thomas, CFO & Chief Bus. Officer (Age 49)Ms. Ran Zheng, Chief Technical OfficerProf. Bobby Gaspar Ph.D., M.D., Chief Scientific Officer, Director & Member of Scientific Advisory Board (Age 54) When did Orchard Therapeutics IPO? (ORTX) raised $200 million in an initial public offering on Wednesday, October 31st 2018. The company issued 13,300,000 shares at $14.00-$16.00 per share. J.P. Morgan, Goldman Sachs and Cowen acted as the underwriters for the IPO and Wedbush PacGrow was co-manager. What is Orchard Therapeutics' stock symbol? Orchard Therapeutics trades on the NASDAQ under the ticker symbol "ORTX." Who are Orchard Therapeutics' major shareholders? Orchard Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include RA Capital Management L.P. (10.66%), Wellington Management Group LLP (2.44%), Vivo Capital LLC (1.67%), ArrowMark Colorado Holdings LLC (1.53%), Driehaus Capital Management LLC (1.48%) and Janus Henderson Group PLC (1.01%). View institutional ownership trends for Orchard Therapeutics. Which major investors are selling Orchard Therapeutics stock? ORTX stock was sold by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., Wellington Management Group LLP, Cormorant Asset Management LP, Canada Pension Plan Investment Board, Ghost Tree Capital LLC, Nuveen Asset Management LLC, Driehaus Capital Management LLC, and Alps Advisors Inc.. View insider buying and selling activity for Orchard Therapeutics. Which major investors are buying Orchard Therapeutics stock? ORTX stock was acquired by a variety of institutional investors in the last quarter, including RA Capital Management L.P., Vivo Capital LLC, Janus Henderson Group PLC, ArrowMark Colorado Holdings LLC, Casdin Capital LLC, State Street Corp, Two Sigma Investments LP, and Two Sigma Advisers LP. View insider buying and selling activity for Orchard Therapeutics. How do I buy shares of Orchard Therapeutics? Shares of ORTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Orchard Therapeutics' stock price today? One share of ORTX stock can currently be purchased for approximately $9.32. How big of a company is Orchard Therapeutics? Orchard Therapeutics has a market capitalization of $906.50 million and generates $2.51 million in revenue each year. The company earns $-163,420,000.00 in net income (profit) each year or ($1.75) on an earnings per share basis. Orchard Therapeutics employs 180 workers across the globe. What is Orchard Therapeutics' official website? The official website for Orchard Therapeutics is www.orchard-tx.com. How can I contact Orchard Therapeutics? Orchard Therapeutics' mailing address is 108 CANNON STREET, LONDON X0, EC4N 6EU. The company can be reached via phone at 011-44-0-203-3846700. This page was last updated on 5/26/2020 by MarketBeat.com Staff
